Introduction Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous
system. Monoclonal antibodies (mAbs) have shown efficacy in reducing MS relapse rates …

Introduction: Natalizumab is a humanized monoclonal antibody highly effective in relapsing-
remitting multiple sclerosis (MS). Important concerns about its safety have been pointed out …

A 43‐year‐old female with multiple sclerosis developed urethral melanoma. The only
potential risk factor was treatment with natalizumab, a humanized monoclonal antibody …

Therapy of multiple sclerosis (MS) with disease-modifying agents such as natalizumab or
fingolimod has been associated with the development of cutaneous melanoma. Here we …

Natalizumab is a monoclonal antibody directed against the α4 chain of the very late
activating antigen 4 and α4β7 integrins, present on the leukocytes surface, used as …

Background: Over the past 20 years, the treatment scenario of multiple sclerosis (MS) has
radically changed, and an ever-increasing number of disease-modifying treatments has …

Introduction: The sudden eruption of melanocytic nevi has been associated with a number of
conditions, such as bullous skin diseases, immunodeficiency and immunosuppression. The …

Natalizumab (NTZ) is a monoclonal antibody targeting the α4β1 integrin (CD49d/CD29),
very late antigen-4 (VLA-4), which is approved for treatment of relapsing-remitting multiple …

Natalizumab is the first humanized moclonal antibody indicated in the treatment of relapsing-
remitting multiple sclerosis (RRMS). Based on its remarkable efficacy in reducing disease …

We present two natalizumab‐treated multiple sclerosis patients who developed
glioblastoma multiforme (GBM) with variable outcomes. One patient had an isocitrate …